<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03915626</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00076010</org_study_id>
    <nct_id>NCT03915626</nct_id>
  </id_info>
  <brief_title>Effect of Heat on Rivastigmine TDS Products</brief_title>
  <official_title>Determination of Serum Rivastigmine Levels After Using Rivastigmine Transdermal Delivery Systems With and Without Standardized Heat Application in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is designed to measure the amount of medicine in blood over time after&#xD;
      the patch is placed on the skin with and without external heat application.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Actual">May 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rivastigmine concentration of collected serum samples</measure>
    <time_frame>0-12 hours for each subject for each of the four study arms (10-12 weeks)</time_frame>
    <description>rivastigmine in serum</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>RLD patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RLD patch with heat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RLD rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>generic patch with heat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>generic rivastigmine patch (4.6 mg/24 hours); worn for 9 hours; 90 min heat application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine (RLD) transdermal patch</intervention_name>
    <description>brand name patch</description>
    <arm_group_label>RLD patch</arm_group_label>
    <arm_group_label>RLD patch with heat</arm_group_label>
    <other_name>brand name patch</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine (generic) transdermal patch</intervention_name>
    <description>generic patch</description>
    <arm_group_label>generic patch</arm_group_label>
    <arm_group_label>generic patch with heat</arm_group_label>
    <other_name>generic patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or non-pregnant, non-lactating women who are of any ethnic background between the&#xD;
             age of 18 to 45 years old&#xD;
&#xD;
          2. Subjects must be non-smokers/tobacco users (must have refrained from the use of&#xD;
             nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars,&#xD;
             chewing tobacco, snuff, gum, patches or electronic cigarettes) over the previous 2&#xD;
             months and are not currently using tobacco products&#xD;
&#xD;
          3. Provide written informed consent before initiation of any of the study procedures&#xD;
&#xD;
          4. Agree not to participate in another clinical trial/study or to participate in an&#xD;
             investigational drug study for at least one month after the last study session&#xD;
&#xD;
          5. Able to adhere to the study restrictions and protocol schedule&#xD;
&#xD;
          6. Able to participate in all study sessions&#xD;
&#xD;
          7. Subjects deemed to be healthy as judged by the Medically Accountable Investigator&#xD;
             (MAI) and determined by medical history, physical examination and medication history&#xD;
&#xD;
          8. Negative urine drug screening test (cannabinoids, amphetamines, barbiturates,&#xD;
             benzodiazepine, cocaine, methadone, opiates, PCP)&#xD;
&#xD;
          9. Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb),&#xD;
             platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN),&#xD;
             creatinine, alanine transaminase (ALT) and aspartate aminotransferase (AST)&#xD;
&#xD;
         10. Have normal screening laboratories for urine protein and urine glucose&#xD;
&#xD;
         11. Female subjects must be of non-childbearing potential (as defined as surgically&#xD;
             sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more&#xD;
             than 1 year), or if of childbearing potential must be non-pregnant at the time of&#xD;
             enrollment and on the morning of each procedure day, and must agree to use reliable&#xD;
             hormonal or barrier birth control such as implants, injectables, combined oral&#xD;
             contraceptives, some intrauterine devices (IUDs), sexual abstinence or a vasectomized&#xD;
             partner&#xD;
&#xD;
         12. Agree not to donate blood to a blood bank throughout participation in the study and&#xD;
             for at least three months after last procedure day&#xD;
&#xD;
         13. Have a normal ECG; must not have the following to be acceptable: pathologic Q wave&#xD;
             abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right&#xD;
             bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats&#xD;
             per minute)&#xD;
&#xD;
         14. Have normal vital signs:&#xD;
&#xD;
               -  Temperature 35-37.9°C (95-100.3°F)&#xD;
&#xD;
               -  Systolic blood pressure 90-140 mmHg&#xD;
&#xD;
               -  Diastolic blood pressure 60-90 mmHg&#xD;
&#xD;
               -  Heart rate 55-100 beats per minute&#xD;
&#xD;
               -  Respiration rate 12-20 breaths per minute&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant, lactating, breast feeding or have a positive serum pregnancy&#xD;
             test at enrollment or positive urine pregnancy test on the morning of any study&#xD;
             session&#xD;
&#xD;
          2. Smokers/tobacco users (current use or use over the previous 2 months of&#xD;
             nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars,&#xD;
             chewing tobacco, snuff, gum, patch or electronic cigarettes)&#xD;
&#xD;
          3. Participation in any ongoing investigational drug trial/study or clinical drug&#xD;
             trial/study&#xD;
&#xD;
          4. History of lung, heart, respiratory or blood disease&#xD;
&#xD;
          5. Active positive Hepatitis B, C and/or HIV serologies&#xD;
&#xD;
          6. Positive urine drug screening test&#xD;
&#xD;
          7. Use of chronic prescription medications during the period 0 to 30 days; or&#xD;
             over-the-counter medications (e.g. cholinomimetic drugs [used to treat diseases like&#xD;
             acid reflux in children, glaucoma, dry mouth associated with Sjögren's Syndrome],&#xD;
             anticholinergics [used to treat diseases like asthma, incontinence, gastrointestinal&#xD;
             cramps, and muscular spasms], antihistamines, topical corticosteroids) and short term&#xD;
             (&lt;30 days) prescription medications during the period 0-3 days before a study session&#xD;
             vitamin, herbal supplements and birth control medications not included)&#xD;
&#xD;
          8. Donation or loss of greater than one pint of blood within 60 days of entry to the&#xD;
             study&#xD;
&#xD;
          9. Any prior allergies to rivastigmine, other carbamate derivatives, other ingredients in&#xD;
             the patch, to medical tape products or other skin patches&#xD;
&#xD;
         10. Subject has problems with urinary retention, gastric retention or gastrointestinal&#xD;
             obstruction&#xD;
&#xD;
         11. Subject has continuous spasms, muscle contractions, motor restlessness, rigidity,&#xD;
             slowness of movement, tremors or irregular jerky movements&#xD;
&#xD;
         12. Subject has ulcers or gastrointestinal bleeding&#xD;
&#xD;
         13. Subject has asthma or blocked airflow making it hard to breathe (COPD)&#xD;
&#xD;
         14. Received an experimental agent (vaccine, drug, biologic, device, blood product or&#xD;
             medication) within one month before enrollment in this study or expects to receive an&#xD;
             experimental agent during the study&#xD;
&#xD;
         15. Any condition that would, in the opinion of the Medically Accountable Investigator&#xD;
             (MAI), place the subject at an unacceptable risk of injury or render the subject&#xD;
             unable to meet the requirements of the protocol&#xD;
&#xD;
         16. Consumption (food or drink) of alcohol within 24 h prior to dose administration&#xD;
&#xD;
         17. History as either reported by the subject or evident to the investigator of infectious&#xD;
             disease or skin infection or of chronic skin disease (e.g., psoriasis, atopic&#xD;
             dermatitis)&#xD;
&#xD;
         18. History of diabetes&#xD;
&#xD;
         19. Hereditary skin disorders or any skin inflammatory conditions as reported by the&#xD;
             subject or evident to the MAI&#xD;
&#xD;
         20. History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma)&#xD;
             except basal cell carcinomas that were superficial and did not involve the&#xD;
             investigative sites&#xD;
&#xD;
         21. Subject has an obvious difference in skin color between arms or the presence of a skin&#xD;
             condition, excessive hair at the application site (upper arms), sunburn, raised moles&#xD;
             and scars, open sores at application site (upper arms), scar tissue, tattoo, or&#xD;
             coloration that would interfere with placement of products, skin assessment, or&#xD;
             reactions to rivastigmine&#xD;
&#xD;
         22. BMI ≥30 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audra L Stinchcomb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore School of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Clinical Research Center (GCRC) at the University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Audra Stinchcomb</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

